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Background: The aim of this study is to investigate the associations between migraine related disability and
somatosensory amplification, depression, anxiety, and stress.
Method: Fifty-five migraine patients who applied to the outpatient unit of the Neurology Department of Acibadem
University School of Medicine, Maslak Hospital in Istanbul, Turkey, and twenty-eight subjects without migraine were
recruited for the study. The participants were asked to complete a sociodemographic form, Migraine Disability
Assessment Scale (MIDAS), Depression Anxiety Stress Scale, Somatosensory Amplification Scale (SSAS).
Results: Somatosensory amplification scores were significantly higher in the migraineurs than in the control group
(29.85+/−6.63 vs 26.07+/−7.1; p=0.027). Somatosensory amplification scores and depression scores were significantly
higher in migraineurs with moderate and severe disability than in patients with minimal and mild disability (31.7+/−6.4 vs
27.71+/−5.49; p=0.01, 11.27+/−8.7 vs 7.38+/−8.11; p=0.04, respectively). A significant positive correlation was found
between the frequency of migraine attacks for at least three consecutive months (MIDAS A scores) and the SSAS scores
(r=0.363, p=0.007) in migraineurs. The MIDAS total scores were also significantly correlated with the DASS depression
subcale scores (r=0.267, p=0.04), and the DASS stress subscale scores (r=0.268, p=0.05).
Conclusion: Psychological factors, and vulnerability to bodily sensations may incease the burden of migraine. We point
out that the timely assessing of somatic amplification and the evaluation of mental status would help improve the
quality of life of in migraineurs.
Keywords: Migraine, Somatosensory amplification, Migraine disability, Depression, Anxiety, StressBackground
Migraine, which is one of the leading neurological reasons
for seeking medical care [1], is considered a chronic, dis-
abling disease that significantly reduces quality of life
[2,3]. The global prevalence of the adult members of the
population with an active headache disorder are 46% for
headache in general, 11% for migraine, 42% for tension-
type headache and 3% for chronic daily headache [4]. In a
nationwide epidemiological study in Turkey, the lifetime
prevalence of migraine was found to be 10.9% in men and
21.8% in women [5].
Migraine has been reported to be associated with vari-
ous well-known comorbidities [6]- conditions which occur
in people with migraine with greater chance of frequency
than in others [7]. Several studies suggest that mood and* Correspondence: burcugoksan@gmail.com
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in any medium, provided the original work is panxiety disorders are two to ten times more prevalent
among people with migraine than in the general popula-
tion, and greater than 25% of migraineurs meet the criteria
for mood and anxiety disorders [8-10]. Population based
studies demonstrate that depression is comorbid with mi-
graine [11,12]. Major depression has been diagnosed in
40.7% of those with migraine and 16% of those in the con-
trol group [11]. In a study conducted by Lipton et al., 47%
of migraineurs had depression while 17% of respondents
in the nonmigraine group met the depression criteria,
according to the Primary Care Evaluation of Mental Disor-
ders screening questionnaire [12]. Other epidemiological
studies have found that the lifetime prevalence of depres-
sion in migraine ranged from 17% to 42% [13-16]. A
population-based study conducted by Chen et al. showed
that 16% of the chronic migraine sufferers had anxiety dis-
orders [17]. Breslau’s population based prospective study
shows that 24.4% of the migraineurs suffered from anxietyn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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found a greater than 4-fold risk of attempted suicide in
migraineurs compared with controls who have never ex-
perienced headaches above mild intensity [18]. A longitu-
dinal population based study shows that 30% of chronic
migraine sufferers, and 19% of the patients with episodic
migraine have anxiety [16]. Chronic stress is a widely rec-
ognized risk factor for both depression and chronic mi-
graine [19]. It has been shown that psychological stress
plays an important role not only before the onset of mi-
graine [20,21], but also in the maintenance of the disorder,
as well as the transformation from episodic to chronic mi-
graine [22]. It is estimated that episodic migraine (EM)
sufferers develop chronic migraine (CM) at the rate of
2.5% per year [23]. Previous studies have demonstrated
that, when compared to EM, CM is associated with
greater disability and lower quality of life [24-27]. Several
studies support the view that psychiatric comorbidities
can promote the transformation of episodic headaches
into chronic daily headache [28,29]. This transformation
may increase headache related disability, as well as the dif-
ficulty of treating it [13].
Although studies have demonstrated the association
between migraine and psychiatric disorders, less is
known about the relationship between somatic amplifi-
cation and migraine related disability. Barsky et al. first
introduced the notion of somatosensory amplification
[30-32]. It was hypothesized that individuals who
somatize perceive normal bodily sensations as unusually
intense and disturbing. We hypothesize that somatic
amplification together with depression, anxiety and
stress may increase the burden of migraine and increase
the risk of migraine related disability. Thus psychiatric
comorbidity should not be underestimated, but should
be treated promptly.
The present study was designed to determine the rela-
tionship between migraine related disability and somatic
amplification and to consider its association with anxiety,
depression and stress levels. To the best of our know-
ledge this is the fist study to investigate the relationship




Fifty-five of ninety-four consecutive migraine patients
aged between 15 and 50 years who applied to the out-
patient unit of the Neurology Department of Acibadem
University School of Medicine, Maslak Hospital in
Istanbul, Turkey between September 2012 and January
2013 were recruited for the study. Migraine diagnosis
was conducted by two neurologists according to the
International Classification of Headache Disorders, sec-
ond edition (ICHD-II) [33]. Exclusion criteria were therecent use of antidepressant and psychotropic drugs
(“recent use” was determined as 8 weeks or less before
the study since all known antidepressants studied in
clinical trials cause a clinical response in about two-
thirds of patients within 8 weeks of initiating treatment
[34]), acute and chronic psychosis, mental retardation
and illiteracy. Thirty-nine patients were excluded due to
their recent use of psychotropic drugs or unwillingness
to participate in the study. Twenty-eight healthy control
subjects matched in age and sex were recruited at the
same time. The control subjects did not meet the cri-
teria for either migraine or non-migraine headache.
Migraineurs were divided into two groups, CM and EM.
To be classified as CM, a respondent had to report an
average of 15 or more headache days per month within
the past three months. EM was defined as reporting an
average of 14 or fewer headache days per month within
the past three months. In order to evaluate the
sociodemographic and clinical characteristics of the par-
ticipants, they were asked to answer a sociodemographic
questionnaire. After they had been informed about the
study and given written informed consent, the subjects
were asked to fill out a Migraine Disability Assessment
Scale (MIDAS), Depression Anxiety Stress Scale (DASS)
and Somatosensory Amplification Scale (SSAS). All of
the fifty five the subjects were found eligible and they all
agreed to participate in the study. One patient with mi-
graine did not fillout the migraine disability assessment
scale.
The study protocol was conducted in accordance with
the ethical principles stated in the “Declaration of
Helsinki” and approved by the Ethical Committee of
Acibadem University School of Medicine.
Materials
Sociodemographic data form
The sociodemographic form was developed by the inves-
tigators to evaluate sociodemographic characteristics
such as age, sex, education status, marital status, occu-
pational status and clinical characteristics.
Migraine disabilty assessment scale
The disability associated with migraine was assessed
using the validated Turkish version of MIDAS. This has
five questions assessing the number of working days lost
due to migraine over a three month period. MIDAS
gathers information on migraine related disability in
terms of work/study, household work, and leisure acti-
vities on the days when the headache was experienced
[35]. The questions are asked regarding either days of
missed activity or days during which productivity was re-
duced by at least 50%. The total days are summed and
categorized into four grades of severity. The four point
grading system for the MIDAS questionnaire is as






Mean±SD n % Mean±SD n %
Sex
Female 42 76.4 19 67.9
Male 13 23.6 9 32.1
Age 31.99±7.22 31.86±5.77
Migrane and associated symptoms
With aura 3 5.5
Without aura 52 94.5
Episodic 52 94.5
Chronic 3 5.5
Duration of migraine (years)
Duration of attacks (days) 1.66±0.81
Attacks per month 6.02±4.31







None 45 81.8 28 100
Depression 8 14.5
Anxiety 2 3.6
SD Standart deviation, n= number of subject, NAS Numeric analogue scale.
Table 2 MIDAS grades of the migraineurs
MIDAS grade %
Grade I (little/no disability) (n=13) 24.1
Grade II (mild disability) (n=8) 14.8
Grade III (moderate disability) (n=16) 29.6
Grade IV (severe disability) (n=17) 31.5
N= number of subject, MIDAS: Migraine diability assessment scale.
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disability; Grade II (scores ranging from 6 to 10), mild
disability; Grade III (scores ranging from 11–20), moder-
ate disability; Grade IV (scores of 21 or greater), severe
disability. MIDAS A and MIDAS B assess headache fre-
quency and pain intensity (0= no pain; 10= very severe
pain) over a three month period. The Turkish version
of the MIDAS questionnaire was developed by Ertas
et al. [36].
Somatosensory amplification scale
The Somatosensory Amplification Scale evaluates sensi-
tivity to mild bodily sensations which are unpleasant and
disturbing but non-pathological. This self-evaluating
scale developed by Barsky et al. consists of 10 items that
are estimated on a five-point scale ranging from 1 (‘not
at all’) to 5 (‘extremely’) [31]. The statements describe a
physical discomfort which does not indicate a disease.
By summing up the scores a total amplification score is
obtained. The reliability and validity of the Turkish form
was established by Gulec et al. [37].
Depression anxiety stress scale
The Depression Anxiety Stress Scale was used in the
present study for data collection to assess the negative
emotional symptoms among participants. It is a 42 item
self-report inventory designed by Lovibond et al. [38]. It
provides scores on three subscales: depression (14
items), anxiety (14 items) and stress (14 items). Each
item is rated on a four-point Likert scale showing the
frequency or severity of the participants’ experiences
over the last week. This scale was validated to Turkish
by Akin et al. [39].
Statistical analyses
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) version 13.0
(SPSS Inc., Chicago, IL., U.S.A, 2005) The data of catego-
rical variables were demonstrated as counts and percent-
ages. The data of continuous variables were presented as
the mean and standard deviation. The Mann Whitney
U test was used to compare the nonparametric vari-
ables. The correlations between the scales were tested
using Pearson’s Correlation Analysis. The level of statis-
tical significance was set at p<0.05.
Results
Sociodemographic and clinical characteristics
A total of 55 migraineurs answered the questionnaires in
this study. Of the 55 patients, 42 (76.4%) were female
and 13 (23.6%) were male. The mean age of the partici-
pants was 31.98±7.22 (ranging between 15 and 47) years.
72.7% of the migraineurs were employed and 57.4% were
married. Among the 55 migraineurs, 52 (94.5%) hadmigraine without aura, while the remaining 3 patients
(5.5%) had migraine with aura. The mean duration of
migraine was 8.78±6.8 years. 90.9% of the patients had
accompanying symptoms such as photophobia, phono-
phobia, nausea and vomiting. Five of the 55 (9.3%) pa-
tients had vertigo. The mean pain intensity of the
patients was 7.35±1.31 (numerical analogue scale, ran-
ging between 0 and 10). The mean number of attacks
for at least three consecutive months was 17.96±13.04
days. The mean duration of attacks was 1.66±0.81 days.
Three patients (5.5%) suffered from CM Table 1 shows
the sociodemographic and clinical characteristics.
Table 3 Comparison of scores between minimal- mild
disability group and moderate - severe disability group









SSAS 27.71±5.49 31.7±6.4 0.01
DASS depression 7.38±8.11 11.27±8.7 0.04
DASS anxiety 7.9±5.71 11.67±7.95 0.09
DASS stress 14.29±8.6 17.94±7.84 0.1
MIDAS Migraine disability assessment scale, SSAS Somatosensory amplification
scale, DASS Depression anxiety stress scale, n=number of subject.














Depression 34(61.8) 7(12.7) 7(12.7) 4(7.3) 3(5.5)
Anxiety 21(38.2) 8(14.5) 13(23.6) 7(12.7) 6(10.9)
Stress 27(49.1) 7(12.7) 10(18.2) 9(16.4) 2(3.6)
n=number of subject, DASS Depression anxiety stress scale.
Table 6 Comparison of scores between migraineurs and
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The MIDAS scores showed that 13 patients (24.1%) had
minimal disability, 8 (14.8%) patients had mild disability,
16 (29.6%) had moderate disability and 17 (31.5%)
had severe disability (Table 2). The total scores for
the migraine disability assessment scale were signifi-
cantly higher in female patients than in male patients
(38.6±6.03 vs 7.01±1.94; p=0.03). Somatosensory amplifi-
cation scores and depression scores were significantly
higher in migraineurs with moderate and severe disabi-
lity than in patients with minimal and mild disability
(31.7±6.4 vs 27.71±5.49; p=0.01, 11.27±8.7 vs 7.38±8.11;
p=0.04, respectively) (Table 3).
A significant positive correlation was found between
the frequency of migraine attacks for at least three con-
secutive months (MIDAS A scores) and the SSAS scores
(r=0.363, p=0.007) in migraineurs. The level of stress
and anxiety symptoms was significantly associated with
the presence of somatic amplification. Our analysis
showed significant correlations between the somatic
amplification scores and the scores for anxiety (r=0.413,
p=0.002) and stress (r=0.291, p=0.03) (Table 4). The
MIDAS total scores were also significantly correlated
with the DASS depression subcale scores (r=0.267,
p=0.04) and the DASS stress subscale scores (r=0,268,
p=0.05) (Table 4).
According to the DASS scores 38.2% of the patients
had depressive symptoms, 61.8% of them had anxiety
symptoms and 52.7% of the patients had mild, moderate
or severe stress levels. Table 5 shows the grading of








MIDAS total r=0.276 p=0.04 r=0.165 p=0.23 r=0.268 p=0.05
SSAS r=0.196 p=0.15 r=0.413 p=0.002 r=0.291 p=0.03
DASS Depression anxiety stress scale, MIDAS Migraine disability assessment
scale, SSAS Somatosensory amplification scale.Depression, anxiety and stress levels were significantly
higher in the migraine patients than in the healthy con-
trol subjects: the Depression subscale (10.02±8.75 vs
6.96±8.72; p=0.03), the Anxiety Subscale (10.24±7.28 vs
6.96±8.72; p=0.03) and the Stress Subscale (16.51±8.2
vs 12.61±8.79; p=0.02). Somatosensory amplification
scores were significantly higher in the magraineurs than in
the control group (29.85±6.63 vs 26.07±7.1; p=0.027).
Table 6 shows a comparison of the migraineurs’ scores
and those of the control subjects. We also found that the
scores in SSAS (36.0±4.0 vs 29.5 ±6.6; p=0.07), DASS
depression (16.67±18.18 vs 9.63±8.1; p=0.5), anxiety
(13.33±7.77 vs 10.06±7.3; p=0.4) and stress (24.0±7.98 vs
16.08±8.07; p=0.08) scales in patients with CM were
higher than in patients with EM.
Discussion
The present study investigated the association between
migraine disability and somatic amplification in a sample
of 55 migraineurs. It also evaluated the relationship be-
tween migraine disability and psychological distress.
Our findings show that migraineurs had a significantly
higher than average tendency to be aware of bodily sensa-
tions. Somatic amplification scores were significantly higher
in migraine patients than in control subjects. Our results
also point out the role of somatic amplification in migraine
related disability. According to our data migraineurs with
moderate and severe migraine related disability have higher
somatosensory amplification scores than the patients with
minimal and mild disability. Moreover there was a signifi-
cant positive correlation between the SSAS scores and the
frequency of headache for the last three months. Patients
who have an increased attention to unpleasant bodily sen-








SSAS 29.85±6.63 26.07±7.1 0.027
DASS-depression 10.02±8.75 6.96±8.72 0.03
DASS-anxiety 10.24±7.28 7.79±8.27 0.03
DASS-stress 16.51±8.2 12.61±8.79 0.02
SSAS Somatosensory amplification scale, DASS Depression anxiety stress scale.
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attacks which may lead to a lower quality of life.
Psychological distress is well kown to be associated
with increased physical symptoms [40]. Similarly our
findings showed significant correlations between somatic
amplification and level of anxiety and stress. Maizels
et al. revealed that the increased prevalence of somatic
symptoms in headeache patients with psychiatric comor-
bidity is not suprising [41], and somatoform disorders
were diagnosed in the range 6%-22% of patients with
chronic daily headache [42,43]. Researchers have shown
that depression and anxiety disorders are frequently
reported in adults with migraine [8-17]. In this study
38.2% of the migraineurs suffered from depressive symp-
toms. Similarly previous studies showed that the inci-
dence of depressive symptoms ranges from 17% to 42%
[13-16]. Our data shows that 62% of the patients with
migraine had anxiety symptoms. This finding was higher
than the rates reported in studies from Italy (38.1%)
[44], China (38.1%) [45] and the USA (51%) [46].
Consistent with Jelinkski’s study, [47] we found that
migraine related disability was significantly correlated
with the level of depressive symptoms. In our study the
severity of stress was also significantly correlated with
migraine related disability. Our finding supports the ne-
cessity of treatment for psychiatric disorders in migraine
patients since migraine and psychological distress signifi-
cantly reduce the quality of life [13] and lead to a worse
prognosis, chronic disease and a reduced response to
treatment [48]. It has been indicated that migraine co-
morbid with depession or anxiety causes higher medical
costs than does migraine alone [49].
Psychological factors and vulnerability to bodily sensa-
tions may incease the burden of migraine. Some episodic
migraine patients develop chronic migraine through a
transformative process [23,50,51]. Chronic migraine ac-
counts for approximately 50% of all chronic daily headaches
in the general population [52]. Poplation-based studies have
demonstrated that compared to EM, CM is associated with
greater migraine-disability, reduced quality of life, increased
medical and psychiatric comorbidities, increased risk of
medication overuse [16,23,50]. Therefore as Yong et al. say
early diagnosis and treatment for psychiatric comorbidiy
are very important [45]. Yong et al. suggest that if comorbid
depression is not recognized and treated effectively,
succesful headache management is unlikely [45]. Thus
clinicians should be alert to psychological stress and somatic
amplification when evaluating migraine patients.
Among our findings, we point out that the timely assessing
of somatic amplification and the evaluation of psychological
status would prevent migraine from becoming chronic and
turning into a headache from medication overuse. Thus
this strategy would help improve the quality of life of in
migraineurs.Conclusion
Previous studies have examined the psychiatric comor-
bidity and somatic symptoms in migraine patients. To
the best of our knowledge this is the first study to inves-
tigate the association between somatic amplification and
migraine disability. However our study has some limita-
tions. First, our sample size was small and this may pre-
vent our results from being generalized. Moreover we
evaluated psychological distress only by a self-reported
questionnaire. Future studies with a large sample size
and a detailed psychiatric evaluation are needed to in-
vestigate further the influence of somatic amplification
and psychological distress in migraine related disability.
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